Explore the words cloud of the Immune-Image project. It provides you a very rough idea of what is the project "Immune-Image" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||27˙200˙801 €|
|EC max contribution||15˙000˙000 € (55%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-10-01 to 2024-09-30|
Take a look of project's partnership.
|1||STICHTING VUMC||NL (AMSTERDAM)||coordinator||4˙079˙222.00|
|2||ACADEMISCH ZIEKENHUIS GRONINGEN||NL (GRONINGEN)||participant||2˙174˙208.00|
|3||WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER||DE (MUENSTER)||participant||1˙930˙000.00|
|4||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||participant||1˙103˙496.00|
|5||THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE||UK (CAMBRIDGE)||participant||1˙041˙875.00|
|6||VIB||BE (ZWIJNAARDE - GENT)||participant||885˙000.00|
|7||VRIJE UNIVERSITEIT BRUSSEL||BE (BRUSSEL)||participant||728˙329.00|
|8||FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA||ES (BARCELONA)||participant||514˙560.00|
|9||COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES||FR (PARIS 15)||participant||510˙000.00|
|10||STICHTING LYGATURE||NL (UTRECHT)||participant||450˙000.00|
|11||FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON||ES (BARCELONA)||participant||433˙310.00|
|12||LAWRENCIUM LEGAL BV||NL (AMSTERDAM)||participant||400˙000.00|
|13||TTOPSTART BV||NL (UTRECHT)||participant||400˙000.00|
|14||ANTAROS MEDICAL AB||SE (MOLNDAL)||participant||250˙000.00|
|15||EUROPEAN CANCER PATIENT COALITION||BE (BRUXELLES)||participant||100˙000.00|
|16||BAYER AKTIENGESELLSCHAFT||DE (Leverkusen)||participant||0.00|
|17||F. HOFFMANN-LA ROCHE AG||CH (BASEL)||participant||0.00|
|18||IMAGINAB, INC||US (INGLEWOOD CA)||participant||0.00|
|19||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|20||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
|21||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|22||TAKEDA DEVELOPMENT CENTRE EUROPE LTD||UK (LONDON)||participant||0.00|
Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-compliant way, and conduct smart clinical trials, including with novel tracers. To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics. Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will provide novel insights into patient immune status, which will support drug development and treatment decisions. To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists, biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of immunotracer clinical trials.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNE-IMAGE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMMUNE-IMAGE" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More
Bringing a prophylactic Ebola vaccine to licensureRead More